{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-011611","form_type":"8-K","ticker":"USAQ","cik":"0000856984","company_name":"QHSLab, Inc.","filed_at":"2024-03-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:27.066113+00:00","generated_at":"2026-06-04T06:50:19.208660+00:00","sec_items":["7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"QHSLab 2023 revenue up 13% to $1.41M; net loss halved to $(240K)","bullets":["Revenue of $1,408,995, up from $1,243,186 in 2022, driven by allergy kits and digital medicine subscriptions.","Gross margin improved to 56.3% from 49.8%; gross profit $793,607.","Net operating loss reduced to $(240,158) from $(560,539); sales & marketing down to $488,537.","New EHR partnership connects 160,000 medical professionals; evidence-based PHQ-9/GAD-7 improvements shown.","R&D spending increased slightly to $214,008 for proprietary platform enhancements."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-011611","json":"https://secwatch.observer/filing/0001493152-24-011611.json","markdown":"https://secwatch.observer/filing/0001493152-24-011611.md","text":"https://secwatch.observer/filing/0001493152-24-011611.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/856984/000149315224011611/0001493152-24-011611-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/856984/000149315224011611/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T06:50:19.208660+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}